Literature DB >> 10424815

Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy.

P Richard1, R Isnard, L Carrier, O Dubourg, Y Donatien, B Mathieu, G Bonne, F Gary, P Charron, M Hagege, M Komajda, K Schwartz, B Hainque.   

Abstract

Familial hypertrophic cardiomyopathy is a genetically heterogeneous autosomal dominant disease, caused by mutations in several sarcomeric protein genes. So far, seven genes have been shown to be associated with the disease with the beta-myosin heavy chain (MYH7) and the cardiac myosin binding protein C (MYBPC3) genes being the most frequently involved. We performed electrocardiography (ECG) and echocardiography in 15 subjects with hypertrophic cardiomyopathy from a French Caribbean family. Genetic analyses were performed on genomic DNA by haplotype analysis with microsatellite markers at each locus involved and mutation screening by single strand conformation polymorphism analysis. Based on ECG and echocardiography, eight subjects were affected and presented a classical phenotype of hypertrophic cardiomyopathy. Two new mutations cosegregating with the disease were found, one located in the MYH7 gene exon 15 (Glu483Lys) and the other in the MYBPC3 gene exon 30 (Glu1096 termination codon). Four affected subjects carried the MYH7 gene mutation, two the MYBPC3 gene mutation, and two were doubly heterozygous for the two mutations. The doubly heterozygous patients exhibited marked left ventricular hypertrophy, which was significantly greater than in the other affected subjects. We report for the first time the simultaneous presence of two pathological mutations in two different genes in the context of familial hypertrophic cardiomyopathy. This double heterozygosity is not lethal but is associated with a more severe phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424815      PMCID: PMC1734410     

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  20 in total

1.  A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.

Authors:  A A Geisterfer-Lowrance; S Kass; G Tanigawa; H P Vosberg; W McKenna; C E Seidman; J G Seidman
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

Review 2.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment.

Authors:  E D Wigle; H Rakowski; B P Kimball; W G Williams
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

3.  Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene.

Authors:  P Charron; O Dubourg; M Desnos; M Bennaceur; L Carrier; A C Camproux; R Isnard; A Hagege; J M Langlard; G Bonne; P Richard; B Hainque; J B Bouhour; K Schwartz; M Komajda
Journal:  Circulation       Date:  1998-06-09       Impact factor: 29.690

4.  Complete sequence and organization of the human cardiac beta-myosin heavy chain gene.

Authors:  C C Liew; M J Sole; K Yamauchi-Takihara; B Kellam; D H Anderson; L P Lin; J C Liew
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

5.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

Authors:  B J Maron; J M Gardin; J M Flack; S S Gidding; T T Kurosaki; D E Bild
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

6.  Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere.

Authors:  L Thierfelder; H Watkins; C MacRae; R Lamas; W McKenna; H P Vosberg; J G Seidman; C E Seidman
Journal:  Cell       Date:  1994-06-03       Impact factor: 41.582

7.  Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients.

Authors:  B J Maron; J S Gottdiener; S E Epstein
Journal:  Am J Cardiol       Date:  1981-09       Impact factor: 2.778

8.  Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy.

Authors:  P Spirito; B J Maron
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

9.  A myosin missense mutation, not a null allele, causes familial hypertrophic cardiomyopathy.

Authors:  H Nishi; A Kimura; H Harada; Y Koga; K Adachi; K Matsuyama; T Koyanagi; S Yasunaga; T Imaizumi; H Toshima
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

10.  Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy.

Authors:  G Bonne; L Carrier; J Bercovici; C Cruaud; P Richard; B Hainque; M Gautel; S Labeit; M James; J Beckmann; J Weissenbach; H P Vosberg; M Fiszman; M Komajda; K Schwartz
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

View more
  19 in total

Review 1.  Functional, structural, and genetic mitochondrial abnormalities in myocardial diseases.

Authors:  A Brega; J Narula; E Arbustini
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

2.  To screen or not is not the question--it is when and how to screen.

Authors:  A J Marian; R Roberts
Journal:  Circulation       Date:  2003-05-06       Impact factor: 29.690

Review 3.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

4.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

Review 5.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

6.  Clinical utility gene card for: hypertrophic cardiomyopathy (type 1-14).

Authors:  Yigal M Pinto; Arthur Aam Wilde; Ingrid Aw van Rijsingen; Imke Christiaans; Ronald H Lekanne Deprez; Perry M Elliott
Journal:  Eur J Hum Genet       Date:  2011-01-26       Impact factor: 4.246

7.  Screening of sarcomere gene mutations in young athletes with abnormal findings in electrocardiography: identification of a MYH7 mutation and MYBPC3 mutations.

Authors:  Chika Kadota; Takuro Arimura; Takeharu Hayashi; Taeko K Naruse; Sachio Kawai; Akinori Kimura
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

8.  Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Yubao Zou; Jizheng Wang; Xuan Liu; Yilu Wang; Yi Chen; Kai Sun; Shuo Gao; Channa Zhang; Zhimin Wang; Yin Zhang; Xinxing Feng; Ying Song; Yajie Wu; Hongju Zhang; Lei Jia; Hu Wang; Dong Wang; Chaowu Yan; Minjie Lu; Xianliang Zhou; Lei Song; Rutai Hui
Journal:  Mol Biol Rep       Date:  2013-01-03       Impact factor: 2.316

9.  Meta-analysis of cardiomyopathy-associated variants in troponin genes identifies loci and intragenic hot spots that are associated with worse clinical outcomes.

Authors:  Hanna J Tadros; Chelsea S Life; Gustavo Garcia; Elisa Pirozzi; Edward G Jones; Susmita Datta; Michelle S Parvatiyar; P Bryant Chase; Hugh D Allen; Jeffrey J Kim; Jose R Pinto; Andrew P Landstrom
Journal:  J Mol Cell Cardiol       Date:  2020-04-09       Impact factor: 5.000

10.  Combinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in disease.

Authors:  Jennifer Davis; Joseph M Metzger
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.